Lechleiter: R&D breakthroughs on the horizon

01/28/2013 | Forbes

The push for personalized medicine, an emphasis on scientific advances and flourishing research into rare diseases suggest that the U.S. biopharmaceutical industry could be on the brink of a renaissance in drug research and development, writes PhRMA chairman and Eli Lilly and Co. CEO John Lechleiter. An all-time high number of new drugs are in human testing, and more drugs are being developed for diseases without approved therapies in the past 10 years, Lechleiter writes.

View Full Article in:

Forbes

Published in Brief: